Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Abeti R"" wg kryterium: Autor


Wyświetlanie 1-3 z 3
Tytuł :
NH-sulfoximine: A novel pharmacological inhibitor of the mitochondrial F 1 F o -ATPase, which suppresses viability of cancerous cells.
Autorzy :
Strobbe D; Department of Biology, University of Rome 'Tor Vergata', Rome, Italy.
Pecorari R; Department of Biology, University of Rome 'Tor Vergata', Rome, Italy.
Conte O; Department of Biology, University of Rome 'Tor Vergata', Rome, Italy.
Minutolo A; Department of Cell and Developmental Biology, Consortium for Mitochondrial Research (CfMR), University College London, London, UK.
Hendriks CMM; Institute of Organic Chemistry, RWTH Aachen University, Aachen, Germany.
Wiezorek S; Institute of Organic Chemistry, RWTH Aachen University, Aachen, Germany.
Faccenda D; Department of Comparative Biomedical Sciences, The Royal Veterinary College, University of London, London, UK.
Abeti R; Ataxia Centre, Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, Queen Square London, London, WC1N 3BG, UK.
Montesano C; Department of Biology, University of Rome 'Tor Vergata', Rome, Italy.
Bolm C; Institute of Organic Chemistry, RWTH Aachen University, Aachen, Germany.
Campanella M; Department of Comparative Biomedical Sciences, The Royal Veterinary College, University of London, London, UK.; Department of Cell and Developmental Biology, Consortium for Mitochondrial Research (CfMR), University College London, London, UK.; Department of Biology, University of Rome 'Tor Vergata', Rome, Italy.
Pokaż więcej
Źródło :
British journal of pharmacology [Br J Pharmacol] 2020 Oct 10. Date of Electronic Publication: 2020 Oct 10.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Xeroderma pigmentosum: overview of pharmacology and novel therapeutic strategies for neurological symptoms.
Autorzy :
Abeti R; Ataxia Centre, Department of Clinical and Movement Neurosciences, University College London, Institute of Neurology London, London, UK.
Zeitlberger A; Ataxia Centre, Department of Clinical and Movement Neurosciences, University College London, Institute of Neurology London, London, UK.
Peelo C; Ataxia Centre, Department of Clinical and Movement Neurosciences, University College London, Institute of Neurology London, London, UK.
Fassihi H; National Xeroderma Pigmentosum Service, St John's Institute of Dermatology Guy's and St Thomas' Foundation Trust, London, UK.
Sarkany RPE; National Xeroderma Pigmentosum Service, St John's Institute of Dermatology Guy's and St Thomas' Foundation Trust, London, UK.
Lehmann AR; Genome Damage and Stability Centre, University of Sussex, Brighton, UK.
Giunti P; Ataxia Centre, Department of Clinical and Movement Neurosciences, University College London, Institute of Neurology London, London, UK.; National Xeroderma Pigmentosum Service, St John's Institute of Dermatology Guy's and St Thomas' Foundation Trust, London, UK.
Pokaż więcej
Źródło :
British journal of pharmacology [Br J Pharmacol] 2019 Nov; Vol. 176 (22), pp. 4293-4301. Date of Electronic Publication: 2019 Jan 23.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Neurodegenerative Diseases/*drug therapy
Xeroderma Pigmentosum/*drug therapy
Humans ; Neurodegenerative Diseases/etiology ; Neurodegenerative Diseases/genetics ; Neurodegenerative Diseases/metabolism ; Xeroderma Pigmentosum/complications ; Xeroderma Pigmentosum/genetics ; Xeroderma Pigmentosum/metabolism
Czasopismo naukowe
    Wyświetlanie 1-3 z 3

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies